Medicus Pharma

MDCX

Market cap $41M

Medicus Pharma (NASDAQ:MDCX) announced that it has completed enrollment of 90 patients in its Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The study, known as SKNJCT-003, is assessing the safety and efficacy of the company's doxorubicin microneedle array (D-MNA) in patients with nodular BCC.

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a warrant inducement agreement for the immediate exercise of the total outstanding Series A Warrants and Series B Warrants that the Company issued on July 14, 2025 (the "Warrants").

Medicus Pharma (NASDAQ:MDCX) announced that Carolyn Bonner, who currently serving as the company's president, has been appointed to the role of chief financial officer (CFO). Bonner has been acting CFO since September 12, filling the role during the medical leave of former finance chief Jim Quinlan, who has now resigned from the company for health reasons.

Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Carolyn Bonner, currently President of the Company, has also been appointed Chief Financial Officer, effective immediately.

Carolyn Bonner succeeds James (“Jim”) Quinlan who has resigned for health reasons after taking medical leave in September 2025 Carolyn Bonner succeeds James (“Jim”) Quinlan who has resigned for health reasons after taking medical leave in September 2025

Medicus Pharma (NASDAQ:MDCX) marked Men's Health Awareness Month on Monday by underscoring new academic research focused on improving treatment options for prostate and skin cancers, two of the most common cancers affecting men. The biotechnology and life sciences company is advancing the clinical development of novel therapeutic candidates, including non-invasive treatments for basal cell skin cancer and next-generation therapies for advanced prostate conditions.

November is Men's Health Awareness Month, a time to spotlight the latest medical breakthroughs that are transforming how we detect and treat cancer in men.

Medicus Pharma (NASDAQ:MDCX) said on Monday it has applied for a US Food and Drug Administration Commissioner's National Priority Voucher (CNPV) to accelerate review of SkinJect, its investigational microneedle patch designed to non-invasively treat basal cell carcinoma (BCC). The application includes a Statement of Interest outlining how SkinJect's Doxorubicin Microneedle Array (D-MNA) aligns with the FDA's national priorities, which focus on improving cancer care access, affordability and options for patients with rare diseases, the company said.

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / November 17, 2025 / Medicus Pharma Ltd.